Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
Completed
Pfizer
Phase 4
2004-08-01
Women are followed prospectively for 3 months, recording headaches, other symptoms, and
menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan
for 3 months.
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
Completed
University of Pittsburgh
Phase 4
2004-08-01
Women are followed prospectively for 3 months, recording headaches, other symptoms, and
menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan
for 3 months.
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
Completed
GlaxoSmithKline
Phase 3
2006-09-13
An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and
naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water
Completed
Pfizer
Phase 1
2009-04-01
The study will evaluate whether the blood concentrations of eletriptan administered using two
test formulations of oral disintegrating tablets are comparable to those observed with the
standard commercial tablet.
Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water
Completed
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
2009-04-01
The study will evaluate whether the blood concentrations of eletriptan administered using two
test formulations of oral disintegrating tablets are comparable to those observed with the
standard commercial tablet.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
